Editor's note

This ExpertREACT article was originally published on 10 August 2012. Financial results and market positions described reflect the state of knowledge at that date.

H1 2012 vaccine sales approach $9bn

According to VacZine Analytics' analysis, the top five vaccine players sold approximately $4.65bn in Q2 2012, making the first half-year total close to $9bn - marginally above the equivalent H1 2011 figure in reported terms. GSK Biologicals reported $1.2bn in Q2 2012 sales. The company described its vaccine business as essentially "flat" in H1 at £1.5bn, with US and EU sales down 1% and 5% respectively due to adverse prior-year comparisons and continuing austerity measures. EMAP region sales increased 9% on strong tender shipments for Rotarix, Synflorix and Infanrix/Pediarix. GSK also confirmed that Nimenrix (EMA approval) and MenHibrix (FDA approval) had been launched, with the latter's US commercial success dependent on a forthcoming ACIP meeting in Q4 2012.

Sanofi Pasteur reported a 3% increase in Q2 vaccine sales at €783m, supported by a record Southern hemisphere flu season at €167m. Early shipments of approximately 60m doses to the US market were already underway for the forthcoming Northern hemisphere influenza season. Manufacturing delays affected Polio/Pertussis/Hib sales (€273m, -5.2%), though Menactra conjugate meningococcal vaccine continued to perform well despite rising competition from Novartis' Menveo.

Top 5 vaccine sales H1 2012
~$9bn
Marginally higher than the equivalent H1 2011 figure in non-comparable reported terms

Dengue CYD: a pivotal but partial result

The most significant R&D event of the quarter was Sanofi's announcement that its CYD dengue vaccine demonstrated proof of efficacy in a Phase IIb study conducted in 4,002 children aged 4-11 years in Thailand. The vaccine generated antibody responses against all four dengue serotypes but only demonstrated statistically significant protection against three of the four in the intent-to-treat analysis - a result described as both encouraging and complicating for the vaccine's development path. VacZine Analytics noted that the dengue vaccine category represented potentially one of the largest new vaccine opportunities, but that the partial efficacy data would require careful interpretation ahead of the Phase III programme decisions.